An adaptive phase I/II, dose-ranging study to evaluate the safety and feasibility of busulfan conditioning prior to transplant of CD4+ T lymphocytes and CD34+ haematopoietic stem/progenitor cells (HSPCs) transduced with LVSH5/C46 (CAL-1), in adults diagnosed at primary HIV-1 infection who are established on effective combination antiretroviral therapy (ART)

Trial Profile

An adaptive phase I/II, dose-ranging study to evaluate the safety and feasibility of busulfan conditioning prior to transplant of CD4+ T lymphocytes and CD34+ haematopoietic stem/progenitor cells (HSPCs) transduced with LVSH5/C46 (CAL-1), in adults diagnosed at primary HIV-1 infection who are established on effective combination antiretroviral therapy (ART)

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 22 Sep 2016

At a glance

  • Drugs Cal-1-transduced haematopoietic stem progenitor cells (Primary) ; Busulfan
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Calimmune
  • Most Recent Events

    • 06 Sep 2016 Status changed from recruiting to suspended.
    • 08 Jun 2016 Status changed from not yet recruiting to recruiting.
    • 03 Sep 2015 Planned initiation date changed from 30 Jul 2015 to 25 Sep 2015 as reported by Australian New Zealand Clinical Trials Registry
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top